Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THROMBO-STOP: Apixaban for VTE Prevention in Lung Cancer
NCT07160686Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in venous thromboembolism (VTE), sponsored by University of Birmingham. Started Apr 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07160686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160686.